How will the new wave of PD-1 inhibitors change the treatment landscape in NSCLC?
Watch also the other lectures
1. Welcome and Introduction
2. PD1 inhibitors for NSCLC: Where are we now?
3. One molecule, many mechanisms of action: Why all PD1 inhibitors are not the same
5. What is the impact of PD1 inhibitors for NSCLC in your clinic? A case study discussion
Tony Mok AND Anne-Marie C. Dingemans
6. PD1 inhibitors for NSCLC: Future challenges, future potential
7. Exploring the promise of emerging PD1 inhibitors in NSCLC